GlassScriptPhysician profile
Catherine Joy Lee
NPI 1871734038
$199,473.31
in general payments reported to CMS, 2019-2025
17 companies · $57K in 2025
The $57K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,246 · 2020: $9,941 · 2021: $5,808 · 2022: $66K · 2023: $22K · 2024: $30K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $5,124 · Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $61,614.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,469.00 |
| Travel and Lodging | $5,124.37 |
| Food and Beverage | $1,274.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $71,122.40 | 2022-2025 | |
| Incyte Corporation | $63,093.96 | 2022-2025 | Jakafi |
| Kite Pharma, INC. | $23,601.96 | 2019-2023 | Yescarta |
| Jazz Pharmaceuticals INC. | $17,914.89 | 2019-2024 | Defitelio |
| Genzyme Corporation | $13,683.73 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $5,600.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $2,076.00 | 2022 | |
| Kadmon Pharmaceuticals LLC | $2,051.23 | 2020-2021 | |
| Seagen INC. | $95.00 | 2019 | |
| Medexus Pharma, INC. | $91.82 | 2022 | |
| United Therapeutics Corporation | $67.57 | 2024 | Orenitram, Remodulin |
| Novartis Pharmaceuticals Corporation | $60.06 | 2021 | |
| Abbvie INC. | $14.69 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.